FloCyte is delighted to have Phil Marder join us!!
Phil
received his graduate training in microbiology from The Ohio State University.
Upon his graduation, he joined Eli Lilly research labs as an associate cell
biologist. Early in his career, Phil was given the opportunity to introduce flow
cytometry as an enabling technology for Lilly’s drug discovery platforms. In
this hands-on role, Phil provided his company with the powerful flow
applications of immunophenotypic analysis, calcium mobilization, DNA cell cycle
detection and FACS® cell sorting. During the late 1980’s, Phil began
working with clinical development teams to incorporate flow cytometric
technology into drug activity biomarker studies of early clinical trials. During
the late 1990’s, Phil also helped introduce the breakthrough technology of
multiplexed analyte detection (Luminex - xMAP®) to Lilly. Phil’s
vision of using flow cytometric analysis to uncover pharmacodynamic effects on
the surrogate target cells in blood proved to be a boon for Lilly’s drug
development processes. Over the ensuing years, Phil’s research leadership helped
develop more than a dozen of these biomarkers assays for the clinic. More
recently, he helped drive use of these assays in pre-clinical laboratory animal
studies. Phil Marder rose through the ranks at Lilly to eventually lead a group
of six investigators in his role as Research Advisor. During this time, he
co-authored 48 peer-reviewed scientific articles and gave podium presentations
at international conferences. He is internationally recognized for his
leadership in applying flow cytometry technology to multiple stages of new drug
development. These applications include optimization of cell lines for
monoclonal antibody secretion, development of cell lines for neuroscience target
screening, validation of primary cell assays for anti-inflammatory platforms,
and most recently, detection of intracellular phosphoproteins for assaying
kinase inhibitor activity of targeted cancer therapies. Phil retired from Lilly
in 2007 after more than 30 years of outstanding accomplishments including two
Lilly Presidential recognition awards. He has since begun a consulting career
and incorporated Redram Consulting, LLC in order to use his extensive research
experience for working with others in the Pharma/Biotech and Instrument/Reagent
sectors for the purpose of helping them leverage flow cytometry technology for
their own needs. Phil's expertise might just be the answer to one of YOUR
research questions!! Phil can be reached at
phil@redramconsulting.com
Phil
received his graduate training in microbiology from The Ohio State University.
Upon his graduation, he joined Eli Lilly research labs as an associate cell
biologist. Early in his career, Phil was given the opportunity to introduce flow
cytometry as an enabling technology for Lilly’s drug discovery platforms. In
this hands-on role, Phil provided his company with the powerful flow
applications of immunophenotypic analysis, calcium mobilization, DNA cell cycle
detection and FACS® cell sorting. During the late 1980’s, Phil began
working with clinical development teams to incorporate flow cytometric
technology into drug activity biomarker studies of early clinical trials. During
the late 1990’s, Phil also helped introduce the breakthrough technology of
multiplexed analyte detection (Luminex - xMAP®) to Lilly. Phil’s
vision of using flow cytometric analysis to uncover pharmacodynamic effects on
the surrogate target cells in blood proved to be a boon for Lilly’s drug
development processes. Over the ensuing years, Phil’s research leadership helped
develop more than a dozen of these biomarkers assays for the clinic. More
recently, he helped drive use of these assays in pre-clinical laboratory animal
studies. Phil Marder rose through the ranks at Lilly to eventually lead a group
of six investigators in his role as Research Advisor. During this time, he
co-authored 48 peer-reviewed scientific articles and gave podium presentations
at international conferences. He is internationally recognized for his
leadership in applying flow cytometry technology to multiple stages of new drug
development. These applications include optimization of cell lines for
monoclonal antibody secretion, development of cell lines for neuroscience target
screening, validation of primary cell assays for anti-inflammatory platforms,
and most recently, detection of intracellular phosphoproteins for assaying
kinase inhibitor activity of targeted cancer therapies. Phil retired from Lilly
in 2007 after more than 30 years of outstanding accomplishments including two
Lilly Presidential recognition awards. He has since begun a consulting career
and incorporated Redram Consulting, LLC in order to use his extensive research
experience for working with others in the Pharma/Biotech and Instrument/Reagent
sectors for the purpose of helping them leverage flow cytometry technology for
their own needs. Phil's expertise might just be the answer to one of YOUR
research questions!! Phil can be reached at